Risk of Cytokine Release Syndrome After CAR T-Cell Therapy May Vary by Ethnicity
Hispanic patients had significantly higher rates of severe cytokine release syndrome.
Latest News
Latest News
Poziotinib Shows Promise in HER2 Exon 20-Mutant Non-Small Cell Lung Cancer
The confirmed response rate was 27%, and the median progression-free survival was 5.5 months.
Up-to-Date Evidence Confirms Pregnancy Possible After Surviving Breast Cancer
Meta-analysis results confirm that women can achieve a successful pregnancy after surviving breast cancer.
Research Assessment Seeks Evidence to Guide Treatment of MPN With COVID-19
Investigators assessed studies for evidence to guide the management of MPN in patients with COVID-19.
Salvage Autologous Stem Cell Transplantation May Improve Outcomes for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
Protection Against SARS-CoV-2 Wanes Months After BNT162b2 Vaccination
Two studies suggest declining effectiveness of the Pfizer-BioNTech COVID-19 vaccine.
Proteins May Predict Lethal Prostate Cancer in African-American Patients
The proteins were only predictive for African-American patients, not European-American patients.
Higher Rate of Treatment Discontinuation Seen in Real-World Patients With Melanoma
Relapse-free survival outcomes were similar between real-world and clinical trial patients.
Verzenio Plus Endocrine Therapy Approved for HR+, HER2-, Early Breast Cancer
The approval is based on data from the phase 3 monarchE trial.
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...